Repros Therapeutics, Inc. (RPRX)

[docbanker]

You are correct. They missed the endpoint and missed several subendpoints. This was a predictable result if you looked at their prior data and then looked at the generalized level of benefit that placebo pts were seeing in RPRX's studies. This was NBIX's first adventure into a study with a control (and not even a positive control like RPRX has used in prior studies). Efficacy is weak. Didnt I also read that many patients werent allowed narcotics- makes the results that much less impressive- RPRX study had to show an effect above and beyond narcotic use.

NBIX time to fold the tent (and the $100 MM headquarters that you sale leasebacked).